Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects

British Journal of Clinical Pharmacology

Volumn 66, Issue 1, 2008, Pages 36-42

  Mistry, Goutam C ^a   Bergman, Arthur J ^a   Zheng, Wei ^a   Hreniuk, David ^a   Zinny, Miguel A ^b   Gottesdiener, Keith M ^a   Wagner, John A ^a   Herman, Gary A ^a   Ruddy, Marcella ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ProMedica Clinical Research Center   (United States)

Author keywords

DPP 4; Glyburide; MK 0431; Pharmacokinetics; Sitagliptin

Indexed keywords

CYTOCHROME P450 2C9; GLIBENCLAMIDE; SITAGLIPTIN;

ADULT; ANXIETY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VITAL SIGN;

ADULT; CROSS-OVER STUDIES; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PYRAZINES; TRIAZOLES;

EID: 44949219464     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03148.x     Document Type: Article

References (24)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004 27 : 1047 53.
2. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002 287 : 360 72.
3. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999 281 : 2005 12.
4. Merck & Inc. JANUVIA (Sitagliptin Phosphate) [Product Circular]. Whitehouse Station, NJ : Merck & Co., Inc., 2006.
5. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004 89 : 2078 84.
6. Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Bavenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002 25 : 869 75.
7. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004 27 : 2874 80.
8. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006 91 : 4612 9.
9. Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006 28 : 55 72.
10. Vincent SH, Reed JR, Bergman AJ, Elmore CS, Zhu B, Xu S, Ebel D, Larson P, Zeng W, Chen L, Dilzer S, Lasseter K, Gottesdiener K, Wagner JA, Herman GA. Metabolism and excretion of the dipeptidyl peptidase inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 2007 35 : 533 8.
11. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004 64 : 1339 58.
12. Krentz AJ, Bailey CJ. Oral antidiabetic agents current role in type 2 diabetes mellitus. Drugs 2005 65 : 385 411.
13. Kirchheiner J, Brockmoller J, Meineke I, Bauer S, Rohde W, Meisel C, Roots I. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 2002 71 : 286 96.
14. van Giersbergen PL, Treiber A, Clozel M, Bodin F, Dingemanse J. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clin Pharmacol Ther 2002 71 : 253 62.
15. Herman G, Bergman A, Wagner JA. Sitagliptin, a DPP-4 Inhibitor: an Overview of the Pharmacokinetic (PK) Profile and the Propensity for Drug-Drug Interactions (DDI). Abstract. 42nd Annual Meeting of the European Association for the Study of Diabetes, September 14-17, 2006.
16. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005 78 : 675 88.
17. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006 49 : 2564 71.
18. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled on metformin alone. Diabetes Care 2006 29 : 2638 43.
19. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006 28 : 1556 68.
20. Aschner P, Kipnes M, Lunceford J, Sanchez M, Mickel C, Williams-Herman DE Sitagliptin 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006 29 : 2632 7.
21. Bergman AJ, Cote J, Maes A, Zhao J, Roadcap B, Sun L, Valesky R, Yang A, Keymeulen B, De Smet M, Laethem T, Wagner J, Herman G. Sitagliptin (MK- 0431), a selective dipeptidyl-peptidase-IV (DPP-IV) inhibitor, does not affect the pharmacokinetics of simvastatin in humans. Clin Pharm Ther 2006 79 (2 Suppl. S48.
22. Mistry GC, Bergman AJ, Luo WL, Cilissen C, Haazen W, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. J Clin Pharmacol 2007 47 : 159 64.
23. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P for the Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007 9 : 733 45.
24. Brockmoller J, Kirchheiner J, Meisel C, Roots I. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics 2000 1 : 125 51.